Jan 7 (Reuters) - Sana Biotechnology Inc SANA.O:
SANA BIOTECHNOLOGY ANNOUNCES POSITIVE CLINICAL RESULTS FROM TYPE 1 DIABETES STUDY OF ISLET CELL TRANSPLANTATION WITHOUT IMMUNOSUPPRESSION
SANA BIOTECHNOLOGY INC - STUDY IDENTIFIES NO SAFETY ISSUES, HIP-MODIFIED ISLET CELLS EVADE IMMUNE RESPONSES
SANA BIOTECHNOLOGY INC -MRI SHOWS SIGNALS CONSISTENT WITH GRAFT SURVIVAL 28 DAYS AFTER TRANSPLANTATION
Source text: ID:nGNX996qx5
Further company coverage: SANA.O
((Reuters.Briefs@thomsonreuters.com;))